Aurinia Pharmaceuticals won approval from the Food and Drug Administration on Friday evening to market a new medicine for patients with lupus nephritis, a serious autoimmune kidney disease. It’s good news for patients, but the nature of the approval also makes it especially good news for Aurinia and investors.
While the approval of the new drug, called Lupkynis, was expected, the FDA allowed Aurinia to include proprietary dosing instructions in its prescribing label. The dosing instructions help physicians tailor Lupkynis treatment for lupus nephritis patients, but they also strengthen and extend the drug’s patent protection.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
January 25, 2021 at 01:34AM
https://ift.tt/2NsNMCl
Aurinia's FDA approval comes with label offering stronger patent protection - STAT
https://ift.tt/3fbzbE8
Bagikan Berita Ini
0 Response to "Aurinia's FDA approval comes with label offering stronger patent protection - STAT"
Post a Comment